Biotechnology

At ESMO 2026, 3SBio's tivunatamig showcased unprecedented lung cancer survival data, validating Pfizer's record-breaking $1.4B upfront licensing gamble.

As GLP-1s face scrutiny over muscle loss, MetaVia’s DA-1726 aims to redefine obesity treatment by preserving lean mass and targeting liver fat.

As Annexon prepares for a crucial investor event, the focus shifts to vonaprument's potential to preserve vision rather than just slowing lesion growth in GA.

With a 100% response rate in early trials, a novel 'silence and replace' approach to an overlooked muscular dystrophy could redefine genetic medicine.

By centralizing R&D and spinning out single-asset companies, TCG Labs Soleil is redefining capital efficiency and de-risking drug development for biopharma.

As biopharma abandons rare liver disease trials, patients are demanding the FDA overhaul its regulatory framework to accelerate life-saving therapies.

As Micron Biomedical opens its commercial foundry, the hiring of a drug delivery veteran signals a bold push into the booming GLP-1 and biosecurity markets.

By leveraging municipal veterinary labs and an innovative cross-border network, China is quietly redefining agricultural diplomacy along the Belt and Road.

Lynk Pharmaceuticals reports unprecedented efficacy for its new RA drug, but can it escape the dark shadow of safety risks haunting the JAK inhibitor class?

By leveraging updated molecular tumor classifications, US WorldMeds is breathing new life into a targeted brain cancer therapy acquired from Orbus Therapeutics.

Addition Therapeutics is bypassing the limitations of AAV vectors with a novel RNA-based gene insertion platform, targeting obesity and rare diseases.

Life Extension partners with biotech pioneer Intralytix to bring targeted bacteriophages to the supplement aisle, modernizing urinary health.

As global biopharma dealmaking rebounds to record highs, European innovators face a critical funding gap that threatens to export their best science.

Egetis Therapeutics has launched the first FDA-approved therapy for MCT8 deficiency, but navigating the commercial and clinical realities of ultra-rare diseases requires more than just scientific innovation.

Moving beyond rare diseases, MeiraGTx unveils novel gene therapies for ALS and dry AMD alongside critical manufacturing breakthroughs to satisfy regulators.

Actuate Therapeutics prices an $11 million offering to fund its promising cancer drug, elraglusib, but the steep dilution highlights biotech's cash crunch.

A new manufacturing agreement between Gannet BioChem and Re-Vana Therapeutics highlights the critical intersection of polymer science and retinal patient care.

Vertero Therapeutics hits a critical clinical milestone, enrolling 24 patients in a Phase 1b trial of VT-5006 to target Parkinson's at its source in the gut.

With a new CEO and a $1.4 billion Novo Nordisk pact, Orbis Medicines leverages AI to transform injectable biologics into daily pills, expanding access.

Lira Clinical partners with biotech firm Wildtype to launch a groundbreaking skincare line, turning cultivated salmon stem cells into a high-margin beauty asset.